Tri Locum Partners’s Pfizer PFE Stock Holding History

Tri Locum Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,732,935	Closed	-$50.2M	–	31
2024 Q3	$50.2M	Buy	1,732,935 +1,136,016	+190%	+$33.1M	12.01%	1
2024 Q2	$16.7M	Buy	+596,919	New	+$16.4M	4.22%	13
2021 Q3	–	Sell	-202,692	Closed	-$7.94M	–	40
2021 Q2	$7.94M	Buy	+202,692	New	+$7.88M	2.6%	11

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tri Locum Partners's PFE Position: Q4 2024 in Review

Tri Locum Partners sold out of Pfizer (PFE) in Q4 2024, closing a stake of 1,732,935 shares — an estimated $50.2M sold.

Tri Locum Partners first reported a position in PFE in Q2 2021 and held it in 3 quarters. The position peaked at $50.2M in Q3 2024. 2,995 funds tracked by Wall St. Rank hold PFE as of Q4 2024.

Tri Locum Partners reported no remaining Pfizer position as of Q4 2024 after selling out during the quarter.
Tri Locum Partners sold 1,732,935 Pfizer shares in Q4 2024, an estimated $50.2M.
Tri Locum Partners first reported a position in Pfizer in Q2 2021 and held it in 3 quarters.
Tri Locum Partners's Pfizer position peaked at $50.2M in Q3 2024.
2,995 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.

Based on Tri Locum Partners's 13F filing for Q4 2024, filed 14 Feb 2025.